YONKERS, N.Y., March 19 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) announced today that an abstract on AVR118
has been selected for presentation at The American Society of Clinical
Oncology's (ASCO) 40th Annual Meeting to be held in New Orleans, LA, June 5-8,
2004. The American Society of Clinical Oncology (ASCO) is the world's leading
professional organization representing physicians who treat people with
cancer.
The ASCO Annual Meeting is the premiere educational event in the clinical
oncology community. The meeting is targeted to U.S. and international
physicians, academicians, and clinical researchers, as well as oncology
fellows, nurses, social workers, physician assistants, and other healthcare
professionals involved in multidisciplinary clinical cancer care. The 2003
Meeting in Chicago attracted 26,400 attendees from all over the world.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com. Advanced Viral Research Corp.,
based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving
patients' lives by researching, developing and bringing to market new and
effective therapies for viral and other diseases. ADVR's AVR118 represents a
biopolymer that possesses novel immunomodulator activity.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 (Product R)
is not approved by the U.S. Food and Drug Administration or any comparable
agencies of any other countries. There is no assurance that the Company will
be able to secure the financing necessary to continue and/or complete the
clinical trials of AVR118 or satisfy certain other conditions relating to
clinical trials including obtaining adequate insurance on terms acceptable to
the Company or that if completed, clinical trials performed outside the United
States will assist the Company in obtaining FDA or other regulatory approval.
The Company undertakes no obligation to update or revise the information
contained in this announcement whether as a result of new information, future
events or circumstances or otherwise.
Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802
SOURCE Advanced Viral Research Corp.
 back to top
Related links:
http://www.adviral.com
Company News On-Call:
http://www.prnewswire.com/comp/903002.html
CONTACT:
Ronnie Welch or Kelly Cinelli, both of CWR &
Partners, +1-508-222-4802, for Advanced Viral Research Corp.
|
